ThroLy score
The Thrombosis 'Lymphoma predictive score' is a multivariable model for assessing the probability of thromboembolic events in patients with lymphoma.
Characteristics
The ThroLy score was developed and published in 2016 by a group of physicians from Serbia and the United States. As a simple model, it was initially internally validated based on individual clinical and laboratory patient characteristics that identify lymphoma patients at risk for a thromboembolic event. Based on an investigation that was conducted on derivation and validation cohorts, it was determined that the variables independently associated with a risk of thromboembolism in lymphoma patients are: previous venous and/or arterial events; mediastinal involvement; a BMI greater than 30 kg/m2; reduced mobility; extra-nodal localization; neutropenia; and a hemoglobin level less than 100g/L.| Patient characteristics | Assigned score |
| Previous venous thromboembolic event | 2 |
| Reduced mobility | 1 |
| Previous acute myocardial infarction or stroke | 2 |
| Obesity | 2 |
| Extranodal localization | 1 |
| Mediastinal involvement | 2 |
| Neutropenia | 1 |
| Hemoglobin˂100g/L | 1 |
Risk classification
Based on the risk score, patients with lymphoma can be classified into three different risk groups.| Risk group | ThroLy score |
| Low risk | 0-1 |
| Intermediate risk | 2-3 |
| High risk | ≥4 |